Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc. is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development. Among these are an oral tablet for norovirus, an oral influenza vaccine, and VXA-CoV2-1, an oral COVID-19 vaccine candidate. Vaxart has reported data from Phase I and Phase II clinical trials demonstrating favorable safety profiles and immune responses that support further clinical evaluation. In addition to its lead programs, Vaxart is exploring applications of its platform for prophylactic and therapeutic vaccines against other respiratory and enteric pathogens.

Headquartered in South San Francisco, California, Vaxart collaborates with academic institutions and government agencies to advance its oral vaccine technology. The company’s management team brings together experienced professionals in vaccine R&D, regulatory affairs, and commercial strategy, guiding Vaxart through clinical and regulatory milestones. By focusing on ease of administration and global distribution, Vaxart seeks to address unmet needs in vaccine access and public health preparedness.

Key Stats

• Today's Range: $0.36 to $0.40
• 50-Day Range: $0.30 to $0.45
• 52-Week Range: $0.26 to $1.07
• Volume: 356,325 shs
• Average Volume: 2.79 million shs
• Market Capitalization: $89.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

Vaxart Stock Analysis - MarketRank™

Vaxart scored higher than 41% of companies evaluated by MarketBeat, and ranked 775th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Vaxart has a consensus price target of $2.00, representing about 412.8% upside from its current price of $0.39.

Amount of Analyst Coverage

Vaxart has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxart is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxart is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxart has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.30% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Vaxart has recently decreased by 1.57%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxart does not currently pay a dividend.

Dividend Growth

Vaxart does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.30% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Vaxart has recently decreased by 1.57%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

Vaxart has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Vaxart this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxart insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.80% of the stock of Vaxart is held by insiders.

Percentage Held by Institutions

Only 18.05% of the stock of Vaxart is held by institutions.

VXRT Stock Analysis - Frequently Asked Questions

How have VXRT shares performed this year?

Vaxart's stock was trading at $0.6621 at the start of the year. Since then, VXRT stock has decreased by 41.1% and is now trading at $0.39.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) released its quarterly earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The biotechnology company had revenue of $20.88 million for the quarter, compared to analysts' expectations of $2.85 million. Vaxart had a negative trailing twelve-month return on equity of 91.89% and a negative net margin of 122.63%.
Read the conference call transcript.

When did Vaxart's stock split?

Vaxart shares reverse split before market open on Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Who are Vaxart's major shareholders?

Vaxart's top institutional investors include Geode Capital Management LLC (1.02%), Marshall Wace LLP (0.77%), Raymond James Financial Inc. (0.10%) and Invesco Ltd. (0.05%).
View institutional ownership trends.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 120
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Vaxart: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +412.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.95 million
• Net Margins: -122.63%
• Pretax Margin: -121.98%
• Return on Equity: -91.89%
• Return on Assets: -38.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.64
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $47.40 million
• Price / Sales: 1.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.26 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 228,941,000
• Free Float: 222,374,000
• Market Cap: $89.29 million
• Optionable: Optionable
• Beta: 1.33